- Clinicians lack a structured framework for managing reproductive dysfunction in iron overload disorders despite high prevalence rates of gonadal toxicity.
- This systematic review synthesized data from 1,201 men, 2,134 women, and 3,536 pregnancies to evaluate iron induced reproductive and endocrine complications.
- Findings showed hypogonadism in 47.0% of men and primary amenorrhea in 45.7% of women, with 11.2% of pregnancies ending in miscarriage.
- Researchers concluded that iron deposition causes oxidative damage, making early chelation therapy essential to prevent permanent failure of the reproductive axis.
- Physicians should implement standardized gonadal screening and early endocrine monitoring to optimize fertility preservation in patients with systemic iron overload.
The Hidden Burden of Iron Toxicity on Reproductive Health
Iron overload disorders, including hereditary hemochromatosis and transfusion-dependent anemias, present a complex clinical challenge characterized by progressive iron deposition in multiple organ systems [1, 2, 3]. While hepatic and cardiac complications are well-documented, the impact on the hypothalamic-pituitary-gonadal axis (the hormonal system governing reproduction) is frequently underappreciated in routine clinical practice [4, 5, 3]. Chronic iron toxicity triggers oxidative stress and inflammation that can permanently damage the seminiferous epithelium (the site of sperm production) in men and reduce ovarian reserve in women [4, 6, 7]. A systematic analysis of 1,201 men with iron overload revealed that 47.0% suffered from hypogonadism, with 17.6% presenting with azoospermia (a complete absence of sperm in the ejaculate) [4]. Despite the availability of effective iron chelation and phlebotomy, many patients continue to experience significant endocrine morbidity and sexual dysfunction [4, 1, 8]. These findings indicate that iron-induced hormonal and metabolic disturbances significantly dictate long-term fertility and pregnancy outcomes, necessitating early screening and multidisciplinary management [4, 9].
Mechanisms of Iron-Induced Gonadal Damage
The systematic review identifies that gonadal dysfunction in patients with iron overload primarily arises from iron deposition within the hypothalamic-pituitary-gonadal axis, the complex hormonal system governing reproduction. This accumulation of iron triggers a cascade of oxidative stress that disrupts the delicate feedback loops required for normal endocrine function. Beyond the central nervous system, the researchers detailed how iron causes direct oxidative damage to Leydig and Sertoli cells in males. Leydig cells are responsible for testosterone production, while Sertoli cells support the development of sperm. The resulting cellular stress disrupts both testosterone synthesis and spermatogenesis (the process of sperm cell development), providing a mechanistic explanation for why 47.0% of the 1,201 men studied presented with hypogonadism and 37.5% exhibited various sperm abnormalities.
In the analysis of 2,134 women, the pathophysiology involves oxidative damage to ovarian follicles and granulosa cells, which are essential for egg maturation and estrogen production. This damage leads to a reduced ovarian reserve (the remaining quantity and quality of a woman's eggs) and significantly altered hormonal signaling. These cellular changes correlate with the high rates of primary amenorrhea (45.7%) and secondary amenorrhea (20.0%) observed in the cohort, as well as a delayed mean age at menarche of 14.4 ± 2.1 years. The researchers noted that while effective iron chelation therapy reduces the systemic iron burden and can prevent these endocrine complications if initiated early, there is limited evidence supporting the reversal of established reproductive dysfunction.
The clinical impact of iron toxicity is further compounded by systemic endocrine and metabolic disturbances. The study found that conditions such as hypothyroidism, growth hormone deficiency, diabetes mellitus, and cardiovascular disease frequently co-occur with gonadal damage, further aggravating reproductive impairments. Because iron-induced damage to the hypothalamic-pituitary-gonadal axis and the gonads themselves is often irreversible once established, the findings underscore the necessity of optimizing iron control from a young age to preserve reproductive potential and improve long-term quality of life.
Male Reproductive and Sexual Impairment
The systematic review highlights a high prevalence of endocrine and reproductive failure among men with iron overload disorders. In a cohort of 1,201 men, the researchers identified hypogonadism in 47.0% of participants. This condition, characterized by impaired testicular endocrine function, represents the most frequent endocrine complication in this population. The clinical presentation often involves a failure of the testes to produce adequate levels of testosterone, which the authors attribute to the dual impact of iron deposition within the pituitary gland and direct oxidative damage to the Leydig cells.
The impact on fertility is equally pronounced when examining semen quality and sperm production. Among the subset of men specifically assessed for spermatogenesis, the study found that 17.6% presented with azoospermia, which is the complete absence of sperm in the ejaculate. Furthermore, 37.5% of these men exhibited other sperm abnormalities, such as reduced motility or morphological defects. These findings suggest that more than half of the men evaluated for fertility face significant barriers to natural conception due to iron-induced damage to the Sertoli cells and the germinal epithelium.
Beyond hormonal and fertility markers, the researchers noted that erectile dysfunction commonly accompanies hypogonadism in men with iron overload. This intersection of endocrine failure and sexual dysfunction further impairs the quality of life for these patients. Because these reproductive impairments are often linked to irreversible structural damage from iron toxicity, the study emphasizes the importance of early screening and the initiation of chelation therapy before permanent gonadal or pituitary failure occurs.
Female Endocrine Dysfunction and Menstrual Health
The systematic review analyzed data from a large cohort of 2,134 women with iron overload disorders, revealing a high prevalence of menstrual dysfunction and endocrine failure. The researchers found that 45.7% of these women experienced primary amenorrhoea, which is defined as the failure of menses to occur by age 15. This high rate of primary failure suggests that iron toxicity often impacts the hypothalamic-pituitary-gonadal axis before the onset of puberty, preventing the normal initiation of reproductive cycles. Additionally, 20.0% of the women in the study presented with secondary amenorrhoea, the cessation of regular menses for three months or more. These findings indicate that even after the initiation of menstrual cycles, ongoing iron deposition in ovarian follicles and granulosa cells can lead to the premature cessation of reproductive function.
The timing of reproductive development is also significantly affected by systemic iron toxicity. The study reported that the weighted mean age at menarche was delayed at 14.4 ± 2.1 years, a finding that reflects the early impact of iron on hormonal signaling and the maturation of the reproductive system. Despite the clear evidence of endocrine and menstrual impairment, the researchers identified a profound gap in the current medical literature regarding other aspects of female reproductive well-being. Specifically, female sexual health in the context of iron overload has not been investigated at all, leaving clinicians without data on how these disorders affect libido, sexual function, or quality of life in women. This lack of research stands in stark contrast to the documented rates of erectile dysfunction in men, highlighting a critical need for future studies to address this disparity in clinical knowledge.
Obstetric Outcomes and Pregnancy Management
While pregnancy is increasingly achievable for women with iron overload disorders, the systematic review of 3,536 reviewed pregnancies demonstrates that these cases remain clinically complex and frequently require intensive medical intervention. The researchers found that assisted reproductive technology (ART) was required in approximately 20% of cases, a figure that underscores the persistent impact of iron toxicity on natural fertility even when systemic iron levels are managed. Furthermore, the data indicate that early pregnancy loss is a significant concern for this patient population, as miscarriage occurred in 11.2% of the 3,536 reviewed pregnancies. These findings suggest that clinicians must provide close monitoring from the earliest stages of conception to manage the unique risks associated with iron-induced endocrine and metabolic disturbances.
The challenges of iron overload extend into the third trimester and the peripartum period, with a high prevalence of surgical interventions and altered neonatal metrics. The study reported that caesarean section was used in approximately 80% of the 3,536 reviewed pregnancies, a rate significantly higher than that seen in the general population. Neonatal outcomes also reflected the impact of maternal iron toxicity and associated systemic complications. The mean gestational age at delivery was 37.1 ± 3.1 weeks, placing the average birth at the threshold of early term. Additionally, the mean birth weight was 2.64 ± 0.68 kg, which is notably lower than standard averages. These specific data points emphasize the necessity for a multidisciplinary approach to obstetric care, combining hematological control with specialized maternal-fetal medicine to address the high likelihood of surgical delivery and the potential for low birth weight infants.
Systemic Comorbidities and Therapeutic Limitations
The clinical management of iron overload disorders, which encompass thalassaemias, hereditary haemochromatosis, and transfusion-dependent anaemias, requires an understanding of the broad systemic impact of iron toxicity beyond the gonads. In a systematic literature search of studies across PubMed, Scopus, and Web of Science up to May 2025, researchers analyzed data from 1201 men and 2134 women to determine how multi-organ involvement affects reproductive health. The findings indicate that reproductive impairments are frequently aggravated by a constellation of systemic iron-related endocrine and metabolic disturbances. Specifically, patients often present with hypothyroidism, growth hormone deficiency, diabetes mellitus, and cardiovascular disease, all of which can complicate the clinical picture and worsen the prognosis for fertility and successful pregnancy.
Therapeutic intervention centers on the early initiation of iron chelation therapy, which involves the administration of medication to remove excess iron from the body. The study confirms that this intervention effectively reduces the systemic iron burden and is successful in preventing endocrine complications when started before significant tissue damage occurs. However, the researchers highlight a critical clinical limitation: evidence supporting the reversal of established reproductive dysfunction through chelation remains limited. This suggests that once iron deposition has caused structural or functional failure within the hypothalamic-pituitary-gonadal axis, standard chelation protocols may not restore fertility. Consequently, the authors advocate for a multidisciplinary approach that integrates haematology and endocrinology to prioritize early screening and proactive iron control from a young age to preserve reproductive potential.
References
1. Prabhu A, Cargill T, Roberts N, Ryan J. Systematic Review of the Clinical Outcomes of Iron Reduction in Hereditary Hemochromatosis. Hepatology. 2020. doi:10.1002/hep.31405
2. Shah F, Porter JB, Sadasivam N, et al. Guidelines for the monitoring and management of iron overload in patients with haemoglobinopathies and rare anaemias. British Journal of Haematology. 2021. doi:10.1111/bjh.17839
3. Prystacka-Szar D, Rulewska N, Grabowski F, et al. Hereditary hemochromatosis: pathogenesis, symptoms, diagnosis and current treatment - literature review. Journal of Education, Health and Sport. 2025. doi:10.12775/jehs.2025.80.58359
4. Carlomagno F, Tenuta M, Sansone A, et al. Iron overload disorders in adults: a comprehensive review of gonadal function, reproductive, and sexual health.. Human reproduction update. 2026. doi:10.1093/humupd/dmag010
5. Roidos C, Kaltsas A, Symeonidis EN, et al. Sickle Cell Disease and Male Infertility: Pathophysiological Mechanisms, Clinical Manifestations, and Fertility Preservation Strategies—A Narrative Review. Life. 2026. doi:10.3390/life16020192
6. Silva CS, Passos NM, Ribeiro APMR, et al. Functional ovarian reserve in women with Sickle Cell disease: A systematic review. JBRA. 2024. doi:10.5935/1518-0557.20240067
7. Roidos C, Batakoias C, Symeonidis EN, et al. Beta-Thalassemia and Male Infertility: Unraveling the Oxidative Stress Connection—An Up-to-Date Review. Diagnostics. 2024. doi:10.3390/diagnostics14242789
8. Rochira V, Antonio L, Vanderschueren D. EAAclinical guideline on management of bone health in the andrological outpatient clinic. Andrology. 2018. doi:10.1111/andr.12470
9. Vlachodimitropoulou E, Mogharbel H, Kuo KH, et al. Pregnancy outcomes and iron status in β-thalassemia major and intermedia: a systematic review and meta-analysis. Blood Advances. 2024. doi:10.1182/bloodadvances.2023011636